Tequin Related Published Studies
Well-designed clinical trials related to Tequin (Gatifloxacin)
Aqueous humor penetration of gatifloxacin and moxifloxacin eyedrops given in different concentrations in a wick before cataract surgery. [2008.05]
Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis. [2008.03]
An open randomized comparison of gatifloxacin versus cefixime for the treatment of uncomplicated enteric fever. [2007.06.27]
The effect of moxifloxacin and gatifloxacin on long-term visual outcomes following photorefractive keratectomy. [2007.04]
Comparing gatifloxacin and clarithromycin in pneumonia symptom resolution and process of care. [2006.04]
Vitreous penetration of topical moxifloxacin and gatifloxacin in humans. [2006.02]
Comparison of topical gatifloxacin 0.3% and ciprofloxacin 0.3% for the treatment of bacterial keratitis. [2006.02]
Aqueous penetration and biological activity of moxifloxacin 0.5% ophthalmic solution and gatifloxacin 0.3% solution in cataract surgery patients. [2005.11]
The effect of fourth-generation fluoroquinolones gatifloxacin and moxifloxacin on epithelial healing following photorefractive keratectomy. [2005.07]
A comparison of therapeutic regimens containing moxifloxacin 0.5% ophthalmic solution and gatifloxacin 0.3% ophthalmic solution for surgical prophylaxis in patients undergoing LASIK or LASEK. [2005.06]
Randomized, investigator-blinded, multicenter, comparative study of gatifloxacin versus amoxicillin/clavulanate in recurrent otitis media and acute otitis media treatment failure in children. [2005.04]
Randomized, investigator-blinded, multicenter study of gatifloxacin versus amoxicillin/clavulanate treatment of recurrent and nonresponsive otitis media in children. [2005.04]
A randomized, investigator- masked clinical trial comparing the efficacy and safety of gatifloxacin 0.3% administered BID versus QID for the treatment BID versus QID for the treatment of acute bacterial conjunctivitis of acute bacterial conjunctivitis. [2005.03]
Penetration of topically applied gatifloxacin 0.3%, moxifloxacin 0.5%, and ciprofloxacin 0.3% into the aqueous humor. [2005.03]
Ocular penetration of moxifloxacin 0.5% and gatifloxacin 0.3% ophthalmic solutions into the aqueous humor following topical administration prior to routine cataract surgery. [2005.01]
A comparison of the fourth-generation fluoroquinolones gatifloxacin 0.3% and moxifloxacin 0.5% in terms of ocular tolerability. [2004.11]
A study to determine the pharmacokinetics of gatifloxacin following a single oral dose. [2004.09]
Gatifloxacin 400 mg as a single shot or 200 mg once daily for 3 days is as effective as ciprofloxacin 250 mg twice daily for the treatment of patients with uncomplicated urinary tract infections. [2004.06]
Once-daily oral gatifloxacin vs three-times-daily co-amoxiclav in the treatment of patients with community-acquired pneumonia. [2004.06]
A randomised, double-blind, double-dummy comparative study of gatifloxacin with clarithromycin in the treatment of community-acquired pneumonia. [2004.05]
Gatifloxacin 200 mg or 400 mg once daily is as effective as ciprofloxacin 500 mg twice daily for the treatment of patients with acute pyelonephritis or complicated urinary tract infections. [2004.03]
Urinary bactericidal activity, urinary excretion and plasma concentrations of gatifloxacin (400 mg) versus ciprofloxacin (500 mg) in healthy volunteers after a single oral dose. [2004.03]
Gatifloxacin in the treatment of community-acquired pneumonias: a comparative trial of ceftriaxone, with or without macrolides, in hospitalized adult patients with mild to moderately severe pneumonia. [2004.02]
Randomized, open-label, parallel-group, multicenter study of the efficacy and tolerability of IV gatifloxacin with the option for oral stepdown gatifloxacin versus IV ceftriaxone (with or without erythromycin or clarithromycin) with the option for oral stepdown clarithromycin for treatment of patients with mild to moderate community-acquired pneumonia requiring hospitalization. [2003.05]
Bioavailability of gatifloxacin by gastric tube administration with and without concomitant enteral feeding in critically ill patients. [2003.05]
Randomised double-blind comparison of oral gatifloxacin and co-amoxiclav for acute exacerbation of chronic Bronchitis. [2003.03]
Lack of bioequivalence of gatifloxacin when coadministered with calcium-fortified orange juice in healthy volunteers. [2003.01]
Minimal interaction between gatifloxacin and oxycodone. [2002.08]
Oral bioavailability of gatifloxacin in healthy volunteers under fasting and fed conditions. [2002.07]
A multicenter, randomized, investigator-blinded study of 5- and 10-day gatifloxacin versus 10-day amoxicillin/clavulanate in patients with acute bacterial sinusitis. [2002.02]
A randomized, double-blind, multicenter comparison of gatifloxacin versus ciprofloxacin in the treatment of complicated urinary tract infection and pyelonephritis. [2002.02]
Once-daily oral gatifloxacin versus oral levofloxacin in treatment of uncomplicated skin and soft tissue infections: double-blind, multicenter, randomized study. [2001.08]
Cost-effectiveness of gatifloxacin vs ceftriaxone with a macrolide for the treatment of community-acquired pneumonia. [2001.05]
Single-dose gatifloxacin compared with ofloxacin for the treatment of uncomplicated gonorrhea: a randomized, double-blind, multicenter trial. [2001.03]
Comparison of 5-day, short-course gatifloxacin therapy with 7-day gatifloxacin therapy and 10-day clarithromycin therapy for acute exacerbation of chronic bronchitis. [2001.01]
Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. [2000.10]
Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise. [2000.06]
Interchangeability of 400-mg intravenous and oral gatifloxacin in healthy adults. [2000.06]
Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium. [1999.05]
Well-designed clinical trials possibly related to Tequin (Gatifloxacin)
Ketorolac tromethamine LS 0.4% versus nepafenac 0.1% in patients having cataract surgery. Prospective randomized double-masked clinical trial. [2007.11]
Long-term prognostic value of neopterin: a novel marker of monocyte activation in patients with acute coronary syndrome. [2007.06.19]
Acute coronary syndromes and diabetes: Is intensive lipid lowering beneficial? Results of the PROVE IT-TIMI 22 trial. [2006.10]
Cholesterol, C-reactive protein, and cerebrovascular events following intensive and moderate statin therapy. [2006.08]
Fourth-generation fluoroquinolone penetration into the aqueous humor in humans. [2006.06]
Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: an analysis of the PROVE-IT TIMI-22 trial. [2005.05.17]
Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome. [2005.04.21]
C-reactive protein levels and outcomes after statin therapy. [2005.01.06]
Short-course treatment regimen to identify potential antituberculous agents in a murine model of tuberculosis. [2004.04]
Single-dose fluoroquinolone therapy of acute uncomplicated urinary tract infection in women: results from a randomized, double-blind, multicenter trial comparing single-dose to 3-day fluoroquinolone regimens. [2002.03]
Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections. [2001.10]
Other research related to Tequin (Gatifloxacin)
Evaluation of gatifloxacin penetration into skeletal muscle and lung by microdialysis in rats. [2008.06.24]
A multi-center randomised controlled trial of gatifloxacin versus azithromycin for the treatment of uncomplicated typhoid fever in children and adults in Vietnam. [2008.05.21]
Ocular Penetration and Pharmacokinetics of Topical Gatifloxacin 0.3% and Moxifloxacin 0.5% Ophthalmic Solutions After Keratoplasty. [2008.04]
Radiation recall dermatitis with gatifloxacin: a review of literature. [2008.04]
Corneal perforation associated with topically applied gatifloxacin. [2008.04]
Gatifloxacin treatment for chronic prostatitis: a prospective multicenter clinical trial. [2008.04]
In vitro evaluation of the antimicrobial activity of meropenem in combination with polymyxin B and gatifloxacin against Pseudomonas aeruginosa and Acinetobacter baumannii. [2008.04]
In vivo therapeutic effect of gatifloxacin on BALB/c mice infected with Nocardia brasiliensis. [2008.04]
Anxiogenic and proconvulsant effect of gatifloxacin in mice. [2008.02.02]
A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. [2008.02]
Gatifloxacin produces both hypoglycemia and hyperglycemia: a retrospective study. [2008.02]
Antimicrobial efficacy of prophylactic gatifloxacin 0.3% and moxifloxacin 0.5% in patients undergoing phacoemulsification surgery. [2008.01]
Prevalence of and risk factors for dysglycemia in patients receiving gatifloxacin and levofloxacin in an outpatient setting. [2008.01]
The ocular penetration of levofloxacin 1.5% and gatifloxacin 0.3% ophthalmic solutions in subjects undergoing corneal transplant surgery. [2007.12]
Study on the ocular pharmacokinetics of ion-activated in situ gelling ophthalmic delivery system for gatifloxacin by microdialysis. [2007.12]
Corneal wound healing in New Zealand White Rabbits following anterior keratectomy and treatment with moxifloxacin ophthalmic solution 0.5% or gatifloxacin ophthalmic solution 0.3%. [2007.12]
Elevated gatifloxacin and reduced rifampicin concentrations in a single-dose interaction study amongst healthy volunteers. [2007.12]
Pharmacokinetics-pharmacodynamics of gatifloxacin in a lethal murine Bacillus anthracis inhalation infection model. [2007.12]
Effects of gatifloxacin and levofloxacin on rates of hypoglycemia and hyperglycemia among elderly hospitalized patients. [2007.11]
Gatifloxacin-associated hypoglycemia. [2007.11]
Oral gatifloxacin in the outpatient treatment of children with cancer fever and neutropenia. [2007.10.15]
Pharmacokinetics and pharmacodynamics of gatifloxacin in children with recurrent otitis media: application of sparse sampling in clinical development. [2007.09]
Antipneumococcal activity of ertapenem compared with gatifloxacin in a temperature-sensitive murine model of acute pneumonia. [2007.08]
Gatifloxacin biodegradable implant for treatment of experimental osteomyelitis: in vitro and in vivo evaluation. [2007.08]
Gatifloxacin in combination with rifampicin in a murine tuberculosis model. [2007.08]
Penetration of gatifloxacin eye drops into the aqueous humor in humans. [2007.07]
Evaluation of gatifloxacin pharmacokinetics and pharmacodynamics in severely ill adults in a medical Intensive Care Unit. [2007.06]
Zymar (Gatifloxacin 0.3%) shows excellent Gram-negative activity against Serratia marcescens and Pseudomonas aeruginosa in a New Zealand White rabbit keratitis model. [2007.06]
High performance liquid chromatography for quantification of gatifloxacin in rat plasma following automated on-line solid phase extraction. [2007.05.09]
Prophylactic gatifloxacin therapy in prevention of bacterial keratitis in a rabbit laser in situ keratomileusis model. [2007.05]
Antimicrobial efficacy of gatifloxacin and moxifloxacin with and without benzalkonium chloride compared with ciprofloxacin and levofloxacin against methicillin-resistant Staphylococcus aureus. [2007.04]
Population pharmacokinetic model for gatifloxacin in pediatric patients. [2007.04]
Selection of a gyrA mutation and treatment failure with gatifloxacin in a patient with Streptococcus pneumoniae with a preexisting parC mutation. [2007.02]
Aqueous humor penetration of gatifloxacin and moxifloxacin eyedrops given by different methods before cataract surgery. [2007.01]
Antacid interaction with new quinolones: dose regimen recommendations based on pharmacokinetic modeling of clinical data for ciprofloxacin, gatifloxacin and norfloxacin and metal cations. [2007.01]
[Status epilepticus and gatifloxacin] [2007.01]
Pharmacokinetics of gatifloxacin after a single oral dose in healthy young adult subjects and adult patients with chronic bronchitis, with a comparison of drug concentrations obtained by bronchoscopic microsampling and bronchoalveolar lavage. [2007.01]
Gatifloxacin-induced severe hypoglycemia in a patient with type 2 diabetes mellitus. [2006.12]
Gatifloxacin induced abnormalities in glucose homeostasis in a patient on glimepiride. [2006.12]
Gatifloxacin-induced dysglycemia. [2006.11.01]
Acute endophthalmitis in eyes treated prophylactically with gatifloxacin and moxifloxacin. [2006.11]
Gatifloxacin-induced hyperglycemia: a case report and summary of the current literature. [2006.11]
[Clinical investigation on administration method of gatifloxacin based on PK/PD theory] [2006.10]
The effects of topical moxifloxacin 0.5% ophthalmic solution and gatifloxacin 0.3% solution on corneal healing after bilateral photorefractive keratectomy. [2006.10]
Comparison of wound healing in pigmented rabbits receiving moxifloxacin or gatifloxacin after creation of corneal flap or penetrating corneal incision. [2006.10]
Comparison of the Effect of Moxifloxacin and Gatifloxacin on Corneal Epithelial Wound Healing in the Rabbit Model. [2006.10]
Comparison of the biocompatibility of gatifloxacin 0.3% and moxifloxacin 0.5%. [2006.10]
Anticoagulation-related outcomes in patients receiving warfarin after starting levofloxacin or gatifloxacin. [2006.10]
Gatifloxacin pharmacokinetics in healthy men and women. [2006.10]
Sequential therapy using high-dose esomeprazole-amoxicillin followed by gatifloxacin for Helicobacter pylori infection. [2006.09.01]
Susceptibility testing of clinical isolates of pseudomonas aeruginosa to levofloxacin, moxifloxacin, and gatifloxacin as a guide to treating pseudomonas ocular infections. [2006.09]
|
